Michael Alfieri
Known title: Principal Financial OfficerCIK: 0001744687
Michael Alfieri's purchase track record
Michael Alfieri has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/18/2026 | ALDX | $7K | +28.9% | -3.5% | +14.0% |
| 8/13/2025 | ALDX | $13K | -1.3% | -0.9% | +7.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ALDX | ▲ Buy | Open Market | 5,000 | $7K | 3/18/2026 | View on chart |
| ALDX | ▲ Buy | Open Market | 2,500 | $13K | 8/13/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Biotech Sector News Dominates; No Specific ALDX Updates
Recent news coverage focuses on clinical trial results for other biotechnology companies, such as ACAD and Vertex, rather than Aldeyra Therapeutics. There are no new company-specific announcements or trial updates for ALDX in the provided reports. The stock is currently trading near its 52-week low, reflecting broader sector sentiment rather than isolated corporate news.
Biotech Sector News Dominates; No Specific ALDX Updates. Recent news coverage focuses on clinical trial results for other biotechnology companies, such as ACAD and Vertex, rather than Aldeyra Therapeutics. There are no new company-specific announcements or trial updates for ALDX in the provided reports. The stock is currently trading near its 52-week low, reflecting broader sector sentiment rather than isolated corporate news.